

FACULTY

Co-chairs

S. Anker (GER)
G. Filippatos (GRE)
P. Ponikowski (POL)
F. Ruschitzka (SUI)
W. Abraham (USA)

M. Lainscak (SLO)
L. Lund (SWE)
A. Mebazaa (FRA)
M. Möckel (GER)
I. Piña (USA)
K. Prasad (UK)
G. Rosano (ITA)
L. Stevenson (USA)
K. Swedberg (SWE)
A. Voors (NL)

Faculty members

J. Butler (USA)
A. Coats (UK)
K. Dickstein (NOR)
G. Hasenfuß (GER)

GENERAL INFORMATION

Where?

Hotel Aston La Scala
12 avenue Félix Faure
06000 Nice, France.

Target audience?

All professionals interested in Heart failure guidelines and clinical trials in Heart Failure.

General information?

Translational Medicine Academy
Charles Schoen
charles.schoen@tmacademy.org
+33 6 08 18 77 08

Isabelle Méjean-Plé
imejean@tmacademy.org
+33 6 77 12 77 98


REGISTRATION

Registration on TMA website: www.tmacademy.org

In collaboration with:



Come and learn more about the
HEART FAILURE GUIDELINES
in 2016!



Closed Guidelines Forum

PROGRAM

The Translational Medicine Academy is an international academic foundation that provides patients, caregivers and families, educational programs that promote meaningful dialogue between healthcare professional and patient and adherence to appropriate treatment plans.

Heart Failure Association of the ESC - Mission Statement:
« To improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research. »

Why an HF Guidelines Closed Forum?

- Educate interested professionals in a transparent way and create a meaningful dialogue about the guidelines elaboration process.
- A better understanding of the processes involved in developing guidelines and the resulting recommendations will help companies that develop the drugs, devices or diagnostic tools that are analyzed in these guidelines to initiate better and more appropriate development programs for the future. This could then also translate into earlier and more efficient development of new diagnostic and therapeutic modalities for patients.

Discussion process during the meeting

Presentations are not handed out and there will be no published proceedings.

Day 1

12.00-13.00 **Lunch**

13.00–13.45 **Heart Failure Guideline Process**

- The ESC Guideline development process. *G. Filippatos*
- How are the US Guidelines developed? *I. Piña*
- What Guidelines can say: levels of recommendation, strengths of evidence & the review process. *G. Hasenfuß*
- What is new in the 2016 ESC / HFA Heart Failure Guidelines?
P. Ponikowski

13.45–14.15 **Is the time ready for international harmonized Guidelines?**

- Differences between Guidelines regarding drug therapy. *G. Filippatos*
- Differences between Guidelines regarding device therapy. *K. Dickstein*
- Resolving disputes and complaints about the Guidelines. *A. Coats*
- Panel discussion.

14.15–16.00 **Guidelines Case Studies 1 — How should the ESC treatment algorithm for chronic HF be interpreted and used?**

- PARADIGM-HF and the place of Sacubitril/Valsartan in the treatment algorithm of chronic heart failure? *G. Rosano*
- The US and Canadian recommendations about Paradigm-HF: Too narrow? Too broad? *L. Stevenson*
- General discussion
- Do we need to rethink some recommendations in consideration of: REM-HF, MORE-CARE and Danish ICD trials? *P. Ponikowski*
- The concept of timing and speed in the therapeutic algorithm for chronic HF. *M. Lainscak*

16.00-16.30 **Break**

16.30-17.30 **Guidelines Case Studies 2 — Treatment for acute and chronic heart failure**

- Drugs for acute & chronic HF – Is relieving symptoms dead? *A. Mebazaa*
- How do the Guidelines deal with drugs that (only) improve symptoms, QoL and PROs. *P. Ponikowski*
- What is HFmrEF? *A. Voors*

17.30–18.45 **Guidelines Case Studies 3 — Drugs for special HF scenarios**

- How can data from recent T2DM trials be relevant for heart failure? The example of Empagliflozin and the EMPA-REG OUTCOME trial. *S. Anker*
- How can results from studies in CKD (and results on HF subgroups there) guide HF guidelines? The case of using potassium binders to treat hyperkalemia. *L. Lund*

- Guidelines and treatment adherence advise: The case of getting patients on full RAAS inhibitor dose and make them stay there using potassium binders. *J. Butler*

18.45–19.00 **Ad hoc Q & A session (part 1)**

From 20.00 **Dinner for all faculty & industry guests**

Day 2

8.15–9.00 **Guidelines Case Studies 4 — Disease monitoring to trigger better case: from biomarkers to devices**

- Blood-based and diagnostic biomarkers. *J. Butler*
- Procalcitonin in AHF for guiding antibiotics therapy. *M. Möckel*

09.00–09.45 **Obstructive, central and mixed aetiology sleep apnea: what now?**

- Sleep disorders in HF – Implications of SERVE-HF? *W. Abraham*
- Sleep disorders in HF – Time for new devices? *A. Coats*

09.45-10.15 **Break**

10.15–11.15 **Guidelines Case Studies 5 — Treatments for acute heart failure**

- Prognosis in acute HF – What prognosis? In hospital worsening HF? Post discharge mortality? *L. Stevenson*
- Drugs for acute HF – is QoL any good? *K. Swedberg*
- Device based monitoring technologies. *K. Dickstein*

11.15–12.00 **Guidelines Case Studies 6 — Drugs/Technologies to treat co-morbidities and special cases**

- How to incorporate new data from meta-analyses – The example of beta blockers in AF. *A. Coats*
- Telemedicine. *W. Abraham*

12.00–12.15 **Ad hoc Q & A session (part 2)**

12.15-13.15 **Lunch**

13.15-14.15 **What do CMS/NIH/FDA/EMA regulators expect from the HF Guidelines?**

- Harmonization of Guidelines - an EMA perspective. *K. Prasad*
- What the FDA expects. *I. Piña*
- What the payors expect. *G. Rosano*
- How do guidelines handle the new FDA Expedited Access Pathway (EAP) program: the BeAT-HF trial. *W. Abraham*

14.15–15.00 **Guidelines Case Studies 7 — Novel devices and surgery – ready for (which) recommendations?! Novel devices for HF — ready for routine use?**

- What about valves? *F. Ruschitzka*
- Interventional Heart Failure: Inter-Atrial Shunts. *W. Abraham*

15.15 **Wrap-up**